Comparing the current results to its competitors, Palatin Technologies Inc reported Revenue increase in the 3 quarter 2026 by 0 % year on year. The revenue growth was below Palatin Technologies Inc 's competitors' average revenue growth of 11.77 %, achieved in the same quarter.
Palatin Technologies Inc , slower than the average decrease reported by the company's competitors of -24.75 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -24.75 %
Palatin Technologies Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with numerous pharmaceutical, biopharmaceutical, and biotechnology firms that have established products and technologies. Competitors often possess significantly greater financial, technological, manufacturing, and distribution resources. The obesity market is notably competitive, featuring products such as the GLP-1 receptor agonists Wegovy and Ozempic (semaglutide). Other melanocortin agonists include Imcivree®, marketed by Rhythm Pharmaceuticals, which also has Bivamelagon in Phase 2 clinical trials for hypothalamic obesity. Several large companies developing obesity and diabetes treatments include Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer, Regeneron, and Altimmune.
Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Sources:
Palatin Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Palatin Technologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
